natgillin/translations-raw huggingface dataset:
adjusting a pH value of the cobalt nitrate solution using an alkali solution to be 1.5, adding a preheated oxalic acid solution having a temperature of between 25 and 80°Cand a pH value of 1.5 to the cobalt nitrate solution in the presence of a water bath of between 25 and 80°C, adjusting a pH value of a resulting solution using a dilute alkali solution to be 1.5, immediately filtering the resulting solution to yield a precipitate of cobalt oxalate, washing the precipitate of cobalt oxalate using deionized water to yield a neutral filtrate, wherein, a mole number of oxalic acid in the oxalic acid solution is controlled to be between 2 and 3 times a mole number of cobalt in the cobalt nitrate solution; 
podešavanje pH vrijednosti otopine kobaltovog nitrata korištenjem alkalne otopine da bude 1.5, dodavanje prethodno zagrijane otopine oksalne kiseline koja ima temperaturu od između 25 i 80°C i pH vrijednost od 1.5 u otopinu kobalt nitrata u prisutnosti vodene kupelji od između 25 i 80°C, prilagođavanje pH vrijednosti dobivene otopine koristeći razrijeđenu alkalnu otopinu da bude 1.5, neposredno filtriranje dobivene otopine da se dobije talog kobalt oksalata, ispiranje taloga kobalt oksalata korištenjem deionizirane vode da se dobije neutralni filtrat, pri čemu se, molarni broj oksalne kiseline u otopini oksalne kiseline kontrolira da bude između 2 i 3 puta molarni broj kobalta u otopini kobalt nitrata;
dissolving the cobalt oxide with a dilute nitric acid solution to yield a second cobalt nitrate solution; and 
otapanje kobaltovog oksida s razrijeđenom otopinom dušične kiseline da se dobije druga otopina kobaltovog nitrata; i
evaporating and crystallizing the second cobalt nitrate solution to yield a crystal of Co(NO3)2·6H2O. 
isparavanje i kristalizaciju druge otopine kobaltovog nitrata da se dobije kristal Co(NO3)2·6H2O.
The method of claim 1 or 2, characterized in that in step 6), the dilute nitric acid solution has a concentration of 1 and 3 mol/L. 
Postupak prema zahtjevu 1 ili 2, naznačen time da u koraku 6), otopina razrijeđene dušične kiseline ima koncentraciju od 1 i 3 mol/L.
The method of claim 3, characterized in that in step 6), the dilute nitric acid solution has a concentration of 1 and 3 mol/L. 
Postupak prema zahtjevu 3, naznačen time da u koraku 6), otopina razrijeđene dušične kiseline ima koncentraciju od 1 i 3 mol/L.
The method of claim 1 or 2, characterized in that in step 4), the water bath has a temperature of 70°C, the oxalic acid solution is preheated to 70°C, and the deionized water is preheated to 70°C. 
Postupak prema zahtjevu 1 ili 2, naznačen time da u koraku 4), vodena kupelj ima temperaturu od 70°C, otopina oksalne kiseline se prethodno zagrijava na 70°C, a deionizirana voda se prethodno zagrijava na 70°C.
The method of claim 4, characterized in that in step 4), the water bath has a temperature of 70°C, the oxalic acid solution is preheated to 70°C, and the deionized water is preheated to 70°C. 
Postupak prema zahtjevu 4, naznačen time da u koraku 4), vodena kupelj ima temperaturu od 70°C, otopina oksalne kiseline se prethodno zagrijava na 70°C, a deionizirana voda se prethodno zagrijava na 70°C.
The method of claim 5, wherein in step 4), the water bath has a temperature of 70°C, the oxalic acid solution is preheated to 70°C, and the deionized water is preheated to 70°C. 
Postupak prema zahtjevu 5, naznačen time da u koraku 4), vodena kupelj ima temperaturu od 70°C, otopina oksalne kiseline se prethodno zagrijava na 70°C, a deionizirana voda se prethodno zagrijava na 70°C.
an antibody light chain variable region comprising: 
promjenjivu regiju lakog lanca antitijela koja sadrži:
An isolated nucleic acid or isolated nucleic acids encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 11. 
Izolirana nukleinska kiselina ili izolirane nukleinske kiseline koja kodiraju antitijelo ili njegov fragment koji vezuje antigen prema bilo kojem od patentnih zahtjeva 1 do 11.
An isolated antibody according to claim 17, for use in preventing or treating Alzheimer-'s disease or related tauopathies. 
Izolirano antitijelo prema patentnom zahtjevu 17, za upotrebu u sprječavanju ili liječenju Alzheimerove bolesti ili odgovarajućih tauopatija.
The composition of claim 19, further comprising at least one compound or agent selected from a detectable label, keyhole limpet hemocyanin, tetanus toxoid or a toxoid derived from other pathogenic bacteria, serum albumins, bovine serum albumin, an immunoglobulin molecule or fragment thereof, thyroglobulin, ovoglobulin, a universal T cell epitope, a cytokine, a chemokine, IL-1 a, IL-, IL-2, IL-10, IFN-Y, GM-CSF, MIP1 a, MIP1 β, and RANTES. 
Pripravak iz patentnog zahtjeva 19, naznačeno time da dalje sadrži najmanje jedan spoj ili sredstvo odabrano od biljega koji se može detektirati, hemocijanina iz školjke Megathura crenulata, toksoida tetanusa ili toksoida izvedenog od drugih patogenih bakterija, albumina iz seruma, albumina iz goveđeg seruma, imunoglobulinske molekule ili njihovog fragmenta, tiroglobulina, ovoglobulina, univerzalnog epitopa T-stanice, citokina, kemokina, IL-1 a, IL-, IL-2, IL-10, IFN-Y, GM-CSF, MIP1 a, MIP1 β, te RANTES.
A composition comprising an antibody according to any one of claims 1 to 11, for its use as a drug for the prevention or the treatment of Alzheimer's disease or related tauopathies. 
Pripravak koji sadrži antitijelo prema bilo kojem od patentnih zahtjeva 1 do 11, naznačeno time da je za njegovu upotrebu kao lijek za sprječavanje ili liječenje Alzheimerove bolesti ili odgovarajućih tauopatija.
The article of manufacture according to claim 23, wherein the container is a component of a device or system for delivery of the antibody to a subject. 
Produkt proizvodnje prema patentnom zahtjevu 23, naznačeno time da je spremnik dio naprave ili sustava za isporuku antitijela subjektu.
A medical device comprising the antibody according to any one of claims 1 to 11, wherein the device is suitable for contacting or administering the antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracerebellar, intracerebroventricular, intrathecal, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus, vaginal, rectal, buccal, sublingual, intranasal, and transdermal. 
Medicinska naprava koja sadrži antitijelo prema bilo kojem od patentnih zahtjeva 1 do 11, naznačeno time da je naprava pogodna za dovođenje u doticaj ili davanje antitijela na najmanje jedan način odabran od parenteralno, subkutano, intramuskularno, intravenozno, intraartikularno, intrabronhijalno, intraabdominalno, intrakapsularno, intrakartilaginozno, intrakavitalno, intracelularno, intracerebelarno, intracerebroventrikularno, intratekalno, intrakolikno, intracervikalno, intragastrično, intrahepatično, intramiokardijalno, intraostealno, intrapelvično, intraperikardijalno, intraperitonealno, intrapleuralno, intraprostatično, intrapulmonarno, intrarektalno, intrarenalno, intraretinalno, intraspinalno, intrasinovijalno, intratorakalno, intrauterinalno, intravezikalno, intralezionalno, bolusno, vaginalno, rektalno, bukalno, sublingvinalno, intranazalno, te transdermalno.
An isolated antibody for use according to claim 26, wherein said antibody is administered intravenously, intramuscularly, subcutaneously, intraperitoneally, intranasally, intracerebroventricularly, intrathecally, or as an aerosol. 
Izolirano antitijelo za upotrebu prema patentnom zahtjevu 26, naznačeno time da se rečeno antitijelo daje intravenozno, intramuskularno, subkutano, intraperitonealno, intranazalno, intracerebroventrikularno, intratekalno, ili kao aerosol.
An isolated antibody for use according to any one of claims 26 to 30, wherein said antibody is administered in multiple dosages, equal or different, over a period of at least three months, preferably at least six months. 
Izolirano antitijelo za upotrebu prema bilo kojem od patentnih zahtjeva 26 do 30, naznačeno time da je rečeno antitijelo dano u višestrukim dozama, jednakima ili različitima, u periodu od najmanje tri mjeseca, preferirano najmanje šest mjeseci.
An isolated antibody for use according to any one of claims 26 to 31, wherein said isolated antibody is administered in combination with at least one combination agent chosen among: acetylcholinesterase inhibitors, NMDA receptor antagonists, transition metal chelators, growth factors, hormones, non-steroidal anti-inflammatory drugs (NSAID), antioxidants, lipid lowering agents, selective phosphodiesterase inhibitors, inhibitors of tau aggregation, inhibitors of protein kinases, inhibitors of heat shock proteins, anti-amyloid passive and active immunization, anti-amyloid aggregation inhibitors, and secretase inhibitors. 
Izolirano antitijelo za upotrebu prema bilo kojem od patentnih zahtjeva 26 do 31, naznačeno time da je rečeno izolirano antitijelo dano u kombinaciji s najmanje jednom kombinacijom sredstva odabranog od: inhibitori acetilkolinesteraze, antagonisti NMDA receptora, kelatori prijelaznih metala, faktori rasta, hormoni, nesteroidni protuupalni lijekovi (NSAID), antioksidansi, sredstva za sniženje lipida, odabrani inhibitori fosfodiesteraze, inhibitori tau-agregacije, inhibitori protein-kinaze, inhibitori proteina toplinskog šoka, anti-amiloidna pasivna i aktivna imunizacija, inhibitori anti-amiloidne agregacije, te inhibitori sekretaze.
A method of in vitro diagnosing or screening a subject for the presence of Alzheimer-'s disease or of a related tauopathy, or for determining a subject's risk for developing Alzheimer's disease or a related tauopathy, the method comprising: 
Metoda in vitro dijagnosticiranja ili probiranja subjekta za prisutnost Alzheimerove bolesti ili odgovarajuće tauopatije, ili za prepoznavanje rizika subjekta za razvijanje Alzheimerove bolesti ili odgovarajuće tauopatije, metoda obuhvaća:
determining the presence of a complex comprising pathological tau and the antibody, wherein the presence of the complex is indicative of the presence of Alzheimer's disease or of a related tauopathy associated with the presence of pathological tau. 
određivanje prisutnosti kompleksa koji sadrži patološki tau i antitijelo, gdje je prisutnost kompleksa indikacija prisutnosti Alzheimerove bolesti ili odgovarajuće tauopatije povezane s prisutnošću patološke tau.
A method according to claim 33, wherein the determination of the presence of a complex comprising pathological tau and the antibody is performed in an assay chosen among: competitive and uncompetitive immunoassay, immunoprecipitation, ELISA, western blotting assay, and immunohistochemistry assay. 
Metoda prema patentnom zahtjevu 33, naznačeno time da je određivanje prisutnosti kompleksa koji sadrži patološki tau i antitijelo provedeno u testu odabranom od: kometitivni i nekompetitvni imunotest, imunoprecipitacija, ELISA, Western blotting test, te imunohistokemijski test.
An antibody according to any one of claims 1 to 9 for use in a method for diagnosing or screening a subject for the presence of Alzheimer's disease or of a related tauopathy, or for determining a subject's risk for developing Alzheimer's disease or a related tauopathy, by in vivo imaging. 
Antitijelo prema bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time da je za upotrebu u metodi za dijagnosticiranje ili probiranje subjekta na prisutnost Alzheimerove bolesti ili odgovarajuće tauopatije, ili za određivanje rizika subjekta za razvoj Alzheimerove bolesti ili odgovarajuće tauopatije, in vivo oslikavanjem.
A pharmaceutical composition comprising the salt of claim 4 and at least a pharmaceutically acceptable carrier, excipient, diluent, or a mixture thereof. 
Farmaceutska kompozicija koja sadrži sol prema patentnom zahtjevu 4 i najmanje farmaceutski prihvatljiv nosač, ekscipijent, razrjeđivač ili njihovu smjesu.
The glucokinase activator in combination with metformin for use according to claim 1 or the product for use according to claim 2, wherein the suboptimal amount of metformin is an amount that ranges from 100 mg/day to 500 mg/day. 
Aktivator glukokinaze u kombinaciji s metforminom za uporabu prema patentnom zahtjevu 1 ili proizvod za uporabu prema patentnom zahtjevu 2, pri čemu je suboptimalna količina metformina količina koja je u opsegu od 100 mg/dan do 500 mg/dan.
at least one active agent selected from rosuvastatin and the pharmaceutically acceptable salts thereof, 
najmanje jedno djelatno sredstvo odabrano od rosuvastatina i njegove farmaceutski prihvatljive soli;
at least one pharmaceutically acceptable low moisture excipient having a moisture content of less than 3.0 w/w%, wherein the pharmaceutically acceptable low moisture excipient comprises non-silicified microcrystalline cellulose, and optionally further excipients 
najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo niske vlažnosti koje ima sadržaj vlage manji od 3,0% (masa/masa), pri čemu to farmaceutski prihvatljivo pomoćno sredstvo niske vlažnosti, obuhvaća nesilificiranu mikrokristalnu celulozu; i
The pharmaceutical composition according to claim 1, wherein the active agent is amorphous rosuvastatin calcium. 
Farmaceutski sastav prema zahtjevu 1, naznačen time, da djelatno sredstvo je amorfni rosuvastatin-kalcij.
The pharmaceutical composition according to claim 1 or 2, wherein the active agent has an average particle size of less than 300 µm, preferably less than 250 µm. 
Farmaceutski sastav prema zahtjevu 1 ili 2, naznačen time, da djelatno sredstvo ima prosječnu veličinu čestice koja je manja od 300 μm, poželjno manja od 250μm.
The pharmaceutical composition according to any one of claims 1 to 3, wherein the active agent binds not more than 15 w/w%, more preferably not more than 10 w/w%, still more preferably not more than 8 w/w% and most preferably not more than 5 w/w% of moisture at 25 °C and 90 % relative humidity. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 3, naznačen time, da djelatno sredstvo ne veže na sebe vlagu u količini većoj od 15% (masa/masa), poželjnije ne više od 10% (masa/masa), još poželjnije ne više od 8% (masa/masa), te najpoželjnije ne više od 5% (masa/masa), uz 25°C i relativnu vlažnost od 90%.
The pharmaceutical composition according to any one of claims 1 to 4, wherein the pharmaceutically acceptable low moisture excipient has a moisture content of less than 2.5 w/w%, particularly less than 2.0 w/w%, most preferably less than 1.5 w/w%. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 4, naznačen time, da farmaceutski prihvatljivo pomoćno sredstvo niske vlažnosti, ima sadržaj vlage manji od 2,5% (masa/masa), poželjnije manji od 2,0% (masa/masa), te najpoželjnije manji od 1,5% (masa/masa).
The pharmaceutical composition according to any one of claims 1 to 5, wherein the pharmaceutically acceptable low moisture excipient is capable of binding at least 6 w/w%, preferably at least 9 w/w% of moisture at 25 °C and 90 % relative humidity. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 5, naznačen time, da farmaceutski prihvatljivo pomoćno sredstvo niske vlažnosti, ima mogućnost vezanja vlage u količini od najmanje 6% (masa/masa), poželjnije najmanje 9% (masa/masa), uz 25°C i relativnu vlažnost od 90%.
The pharmaceutical composition according to any one of claims 1 to 6 comprising at least 30 w/w%, more preferably at least 40 w/w%, still more preferably at least 50 w/w%, and most preferably at least 60 w/w% of the pharmaceutically acceptable low moisture excipient. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 6, naznačen time, da on obuhvaća farmaceutski prihvatljivo pomoćno sredstvo niske vlažnosti, u količini od najmanje 40% (masa/masa), još poželjnije najmanje 50% (masa/masa), te najpoželjnije najmanje 60% (masa/masa).
The pharmaceutical composition according to any one of claims 1 to 8, wherein a solution or dispersion of the pharmaceutical composition has a pH of less than 8, particularly in the range of from 6 to less than 8. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 8, naznačen time, da otopina ili disperzija farmaceutskog sastava, ima pH-vrijednost manju od 8, te poželjno u rasponu od 6 do manje od 8.
A packaged pharmaceutical composition comprising the solid pharmaceutical composition according to any one of claims 1 to 9, wherein the solid pharmaceutical composition is present in a low gas permeable primary packaging. 
Pakirani farmaceutski sastav, naznačen time, da obuhvaća čvrsti farmaceutski sastav prema bilo kojem od zahtjeva 1 do 9, pri čemu se čvrsti farmaceutski sastav nalazi u jednom primarnom pakiranju s malom propusnošću za plinove.
A process for the preparation of the pharmaceutical composition according to any one of claims 1 to 9 or the packaged pharmaceutical composition according to claim 10, which process comprises compressing the active agent with at least one excipient in the absence of solvent and optionally coating the obtained composition and/or packaging the obtained composition. 
Postupak za proizvodnju farmaceutskog sastava prema bilo kojem od zahtjeva 1 do 9, ili pakiranog farmaceutskog sastava prema zahtjevu 10, naznačen time, da postupak obuhvaća stlačivanje djelatnog sredstva s najmanje jednim pomoćnim sredstvom ali bez prisutnosti otapala i prema potrebi oblaganje dobivenog sastava i/ili pakiranje dobivenog sastava.
A dry powder inhaler suitable for pulmonary or nasal delivery, comprising an inhaler body (201; 801) and a cartridge (203; 803); the inhaler comprising: 
Inhalator za suhi prah prikladan za plućno ili nazalno davanje, koji sadrži tijelo inhalatora (201; 801) i uložak (203; 803); te inhalator sadrži:
A dry powder inhaler of any of the preceding claims, wherein each cartridge powder compartment lateral vent (209, 309, 409, 509, 609, 709, 809) tapers inwards towards the inner surface of the compartment (205, 305, 405, 505, 605, 705, 805) so as to funnel the air as it passes through the vent into the compartment. 
Inhalator za suhi prah prema bilo kojem od prethodnih zahtjeva, naznačen time da se svaki bočni otvor odjeljka za prah za uložak (209, 309, 409, 509, 609, 709, 809) sužava prema unutra prema unutrašnjoj površini odjeljka (205, 305, 405, 505, 605, 705, 805) kako bi se vodio zrak dok prolazi kroz otvor u odjeljak.
A method of decoding an image, the method comprising: determining a plurality of square maximum coding units from an image and determining a square coding unit which is hierarchically split from a maximum coding unit among the plurality of maximum coding units using information about a coding unit, wherein the information about a coding unit is parsed from a bitstream; 
Postupak za dekodiranje slike, te postupak sadrži: određivanje mnoštva kvadrata maksimalnih jedinica kodiranja iz slike i određivanje kvadrata jedinice kodiranja koja je hijerarhijski razdvojena iz maksimalne jedinice kodiranja između mnoštva maksimalnih jedinica kodiranja korištenjem informacija o jedinici kodiranja, pri čemu se informacija o jedinici kodiranja raščlanjuje iz toka bitova; određivanje najmanje jedne jedinice predviđanja koja je podijeljena iz jedinice kodiranja korištenjem informacija o jedinici predviđanja, pri čemu se informacija o jedinici predviđanja raščlanjuje iz toka bitova;
A container (600) for consumer goods comprising: 
Spremnik (600) za proizvode široke potrošnje koji se sastoji od:
a box (602); and a lid (604) hinged to the box (602) along a hinge line extending across a back wall of the container, the lid being pivotable about the hinge line between a closed position and an open position; 
kutiju (602); i poklopac (604) preklopno spojen na kutiju (602) uzduž preklopne linije koja se pruža duž stražnje stjenke spremnika, poklopac se može zakretati oko preklopne linije između zatvorenog položaja i otvorenog položaja;
A container (600) according to any of the preceding claims, wherein the access aperture of the inner package (606) is defined by one or more lines of weakness in the inner package (606). 
Spremnik (600) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je pristupni otvor unutrašnjeg pakiranja (606) definiran s jednom ili više linija oslabljenja u unutarnjem pakiranju (606).
A container (600) according to claim 2, wherein the adhesive label (608) comprises a further area of the inner surface of the adhesive label (608) permanently affixed to the portion of the inner package (606) bounded by the one or more lines of weakness. 
Spremnik (600) prema zahtjevu 2, naznačen time da naljepnica (608) sadrži dodatno područje unutrašnje površine naljepnice (608) trajno pričvršćeno na dio unutrašnjeg pakiranja (606) omeđeno s jednom ili više linija oslabljenja.
A container (600) according to any of the preceding claims, wherein the adhesive label (608) is partially permanently affixed to the inner package (606). 
Spremnik (600) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da je naljepnica (608) djelomično trajno pričvršćena na unutrašnje pakiranje (606).
A container (600) according to claim 5, wherein the adhesive label (608) is permanently affixed to the inner package (606) by a connection edge of the adhesive label (608) adjacent an edge of the access portion, the connection edge being located towards the back of the top of the inner package. 
Spremnik (600) prema zahtjevu 5, naznačen time da je naljepnica (608) trajno pričvršćena na unutrašnje pakiranje (606) pomoću spojnog ruba naljepnice (608) susjednog rubu pristupnog dijela, te je spojni rub smješten prema stražnjem dijelu vrha unutrašnjeg pakiranja.
A container (600) according to any of the preceding claims, further comprising an inner frame within the inner package (606). 
Spremnik (600) prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da nadalje sadrži unutrašnji okvir unutar unutrašnjeg pakiranja (606).
represents Lys, wherein the -NH2 side chain group is functionalized by one of the groups selected from (S)-4-Carboxy-4-hexadecanoylamino-butyryl- and (S)-4-Carboxy-4-octadecanoylamino-butyryl-, 
predstavlja Lys, pri čemu je -NH2 skupina bočnog lanca funkcionalizirana s jednom od skupina koje se biraju od (S)-4-karboksi-4-heksadekanoilamino-butiril-, (S)-4-karboksi-4-oktadekanoilamino-butiril-.
represents Ile, represents Lys, wherein the -NH2 side chain group is functionalized by one of the groups selected from (S)-4-Carboxy-4-hexadecanoylamino-butyryl- and (S)-4-Carboxy-4-octadecanoylamino-butyryl-, 
predstavlja Lys, pri čemu je -NH2 skupina bočnog lanca funkcionalizirana s jednom od skupina koje se biraju od (S)-4-karboksi-4-heksadekanoilamino-butiril- i (S)-4-karboksi-4-oktadekanoilamino-butiril-,
Device according to claim 1, characterized in that said annular wall (16) of said annular enclosure (15) is positioned at a distance d 2 from the enclosure of the reactor, the distance d 2 varying from 2% to 20% of the diameter of the reactor. 
Uređaj prema zahtjevima 1 ili 2, naznačen time da je navedena prstenasta stjenka (16) navedenog prstenastog prostora (15) postavljena na udaljenosti d2 od kućišta reaktora, te navedena udaljenost d2 varira od 2% do 20% promjera reaktora.
Device according to claim 1, characterized in that said mixing chamber (9) comprises at least one means for deflecting the fluids on at least one of the internal walls of said mixing chamber. 
Uređaj prema bilo kojem od zahtjeva 1 do 11, naznačen time da navedena komora za miješanje (9) sadrži na barem jednoj od unutarnjih stijenki navedene komore za miješanje najmanje jedno sredstvo za skretanje tekućina.
Device according to claim 1, characterized in that it also comprises a dispersal system arranged below said distribution plate (12), said dispersal system comprising at least one dispersal device (19). 
Uređaj prema bilo kojem od zahtjeva 1 do 12, naznačen time da također sadrži sustav raspršivanja koji je smješten ispod navedene razdjelne ploče (12), navedeni sustav raspršivanja sadrži barem jedan uređaj za raspršivanje (19).